Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)

Next Previous
Trial Profile

Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 04 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amubarvimab/romlusevimab-Brii-Biosciences (Primary) ; Bamlanivimab (Primary) ; Camostat mesilate (Primary) ; Cilgavimab/tixagevimab (Primary) ; Cilgavimab/tixagevimab (Primary) ; Interferon beta-1a (Primary) ; Ogalvibart+C144-LS (Primary) ; SAB-185 (Primary) ; Casirivimab/imdevimab
  • Indications COVID 2019 infections; Post acute COVID 19 syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ACTIV-2; Adapt Out COVID

    • Most Recent Events

    • 31 Aug 2023 Results finding association between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19, published in the Journal of Infectious Diseases
    • 31 Aug 2023 Results (n=506) in participants who received bamlanivimab 700 mg in ACTIV-2 from October 2020 to February 2021, determining the frequency and predictors of long COVID after treatment with the monoclonal antibody bamlanivimab , published in the Journal of Infectious Diseases
    • 31 Aug 2023 Results finding association between COVID 19 severity and degree of immunosuppression, published in the Journal of Infectious Diseases
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top